Severe Alopecia Areata

ORLANDO — Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to a late-breaking presentation at the American Academy of Dermatology Annual Meeting.

ORLANDO — Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and eyelashes compared with placebo in adolescents with severe alopecia areata, data show.

Leqselvi demonstrated clinically meaningful improvements long-term in adults with alopecia areata, Sun Pharma announced in a press release.

After 1 year’s worth of hair regrowth among patients treated with baricitinib for severe alopecia areata, treatment withdrawal resulted in a loss of benefit for almost all patients, according to a study.

The FDA has approved Leqselvi 8 mg tablets to treat severe alopecia areata in adults, Sun Pharma announced in a press release.

In a literature review evaluating the findings of two identical phase 3 trials of baricitinib, the oral Janus kinase 1/2 inhibitor was found to be efficacious, safe and “relatively tolerable” in the treatment of severe alopecia areata.

Efficacy and safety outcomes in adolescents treated with ritlecitinib for severe alopecia areata were consistent with adults in the same indication, according to a subgroup analysis of a phase 2b/3 trial.

The FDA has approved Litfulo, a once-daily oral treatment, for the treatment of severe alopecia in individuals aged 12 years and older, Pfizer announced in a press release.

NEW ORLEANS — A second phase 3 trial of deuruxolitinib confirmed the efficacy and tolerability of the drug in adults with moderate to severe alopecia areata, according to a study presented at the American Academy of Dermatology Annual Meeting.